Phase 3 Study of KHK7580

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
This study is designed to evaluate efficacy and safety of KHK7580 orally administered once daily for 32 weeks for patients with secondary hyperparathyroidism receiving peritoneal dialysis. After 32-week treatment period, the subjects will receive KHK7580 in the 20-week extension period to evaluate long-term safety and efficacy.
Epistemonikos ID: 2b959af3917922f7f3b9f31951439903d2d8775b
First added on: May 12, 2024